Jennison Associates
ATRA icon

Jennison Associates’s Atara Biotherapeutics ATRA Stock Holding History

Jennison Associates’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7,228
Closed -$7.05M – 656
2018
Q1 		$7.05M Buy
+7,228
New +$6.59M 0.01% 475
2017
Q2 		– Sell
-1,614
Closed -$829K – 640
2017
Q1 		$829K Buy
+1,614
New +$668K ﹤0.01% 586
2015
Q4 		– Sell
-33,767
Closed -$26.5M – 659
2015
Q3 		$26.5M Buy
33,767
+9,788
+41% +$11.9M 0.03% 397
2015
Q2 		$31.6M Buy
23,979
+189
+0.8% +$217K 0.03% 406
2015
Q1 		$24.7M Buy
23,790
+12,042
+103% +$7.96M 0.02% 422
2014
Q4 		$7.86M Buy
+11,748
New +$7.17M 0.01% 496

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Jennison Associates's ATRA Position: Q2 2018 in Review

Jennison Associates sold out of Atara Biotherapeutics (ATRA) in Q2 2018, closing a stake of 7,228 shares — an estimated $7.05M sold.

Jennison Associates first reported a position in ATRA in Q4 2014 and held it in 6 quarters. The position peaked at $31.6M in Q2 2015. 124 funds tracked by Wall St. Rank hold ATRA as of Q2 2018.

  • Jennison Associates reported no remaining Atara Biotherapeutics position as of Q2 2018 after selling out during the quarter.
  • Jennison Associates sold 7,228 Atara Biotherapeutics shares in Q2 2018, an estimated $7.05M.
  • Jennison Associates first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 6 quarters.
  • Jennison Associates's Atara Biotherapeutics position peaked at $31.6M in Q2 2015.
  • 124 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2018.

Based on Jennison Associates's 13F filing for Q2 2018, filed 2 Aug 2018.